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Gradually, pale grey to brownish/yellowish spiral streaks will form in a vortex pattern in the corneal epithelium ('cornea verticillata'), extending from just below the centre of the cornea to the periphery (see Figures 1a and 1b) .
Cornea verticillata is best observed by slit-lamp examination using a wide-slit beam angled from the side and utilising the light that is backscattered from the iris in order to evaluate the fine opacities. Cornea verticillata has been reported in ~95% of affected males and in ~70% of affected females, in whom it can even be the only apparent manifestation of the disease. 20 The exact mechanism of formation of cornea verticillata is still unknown, but it has been postulated that formation of subepithelial ridges resulting from GL-3 deposition in the sub-epithelial area of the cornea causes variations in density on ophthalmological examination. Besides Fabry disease, cornea verticillata may be observed in patients being treated with a variety of drugs including amiodarone, chloroquine, amodiaquine, meperidine, indomethacin, chlorpromazine and tamoxifen.
Retina
Retinal vascular changes in the form of narrowing of arterioles and corkscrew-like exaggerated dilatation (tortuosity) of retinal and conjunctival veins are not uncommon, particularly in males (see Figure 2 ). These vessel abnormalities are most prominent in the posterior pole. 19, 20 In addition, hypertensive retinopathy or retinal oedema can develop as a result of vascular and renal Fabry disease pathology.
Conjunctiva
Conjunctival vessels with a corkscrew-like appearance and aneurysmal dilatations are frequently observed (see Figure 3 ).
Lens
Anterior capsular or subcapsular deposits in the lens have been described. Classically, whitish, granular spoke-like deposits in the posterior lens constitute the 'Fabry cataract'. 18, 19 Vision Ocular lesions rarely affect vision; however, central retinal artery occlusion causing sudden visual loss has been described, as have cases of ischaemic optic neuropathy. 19, [22] [23] [24] 
Lacrimal Secretion
Reduced lacrimal secretion may occur due to vascular involvement or GL-3 deposition in the lacrimal glands. 25 
Enzyme-replacement Therapy
Recombinant human α-galactosidase A (Fabrazyme ® , agalsidase beta) appears to offer the best choice in patients with Fabry disease based on evidence from controlled clinical trials and open-label studies. [26] [27] [28] [29] With agalsidase beta therapy, complete normalisation of storage of GL-3 in a 
Clinical Course
The wide spectrum of clinical disease spans from the most severe form (Hurler disease) to less aggressive forms of the disease (the Hurler-Scheie and Scheie phenotypes). [31] [32] [33] In Hurler patients, the disease progresses rapidly. Patients are commonly diagnosed at around the age of nine months and cognitive defects and developmental delay usually become apparent before the age of two years. Patients will be severely mentally retarded and have pronounced somatic disease manifestations at the time of early demise, often before the age of 10 years. In more attenuated cases, joint pain and stiffness with difficulty in using the hands (see Figure 4a ), corneal clouding, ear-nose-throat infections and recurrent umbilical hernia generally manifest before the age of two years.
Coarse facial features, hepatomegaly, hearing difficulties and delayed speech development are common. Life expectancy in attenuated forms may be limited to <20 years, whereas Scheie patients with fewer physical symptoms may survive well into adulthood (see Figure 4b ). However, cardiac insufficiency or complications of, for example, spinal surgery may reduce life span if cause-specific treatment and adequate supportive care
are not administered.
Ocular Features
The main ocular manifestations of MPS I include corneal clouding, retinal pigmentary degeneration, glaucoma and optic nerve abnormalities. 6 Prominent, wide-set eyes (shallow orbits, hypertelorism) may be seen in severely affected patients.
Cornea
Corneal opacities are universally present in all forms of MPS I. 31 Fine grey punctate opacities are first seen in the anterior stroma; later, as the disease progresses, they are also seen in the posterior stroma. Progressive corneal opacification is typically diffuse and is associated with photosensitivity and reduced central visual acuity. There are reports of denser clouding in the peripheral cornea in MPS disease with good visual acuity as a result of minimal central corneal involvement, especially in attenuated cases. 34 Corneal grafts may improve visual acuity in such cases (see Figure 5 ). In severe cases, vision is impaired in early childhood and nystagmus may be present. If corneal clouding is detected it is important that the ophthalmologist considers a possible diagnosis of MPS I, particularly in the presence of other suspect clinical symptoms. However, other diseases should also be considered in the differential diagnosis (see Table 1 ). 
Glaucoma
Increased intraocular pressure is not uncommon in MPS I. 31 Accumulation of incompletely degraded GAGs in the trabecular meshwork has been suggested as the primary cause of glaucoma in severe MPS I. Also, it was hypothesised that the meshwork is affected to a greater extent than other anterior segment structures, leading to open-angle glaucoma with progressive, permanent loss of vision and light hypersensitivity. In some patients, progressive shallowing of the anterior chamber and subsequent angle-closure glaucoma with sudden decrease of vision has been described. 37 
Optic Nerve
In severe MPS I, optic atrophy may develop after long-standing optic nerve head oedema, secondary to increased intracranial pressure and 
Mucopolysaccharidosis II (Hunter Disease)
MPS II is caused by a mutation in the gene that encodes the lysosomal enzyme iduronate-2-sulphatase. 30 The disorder is characterised by an X-linked inheritance pattern, but females may also develop disease manifestations partly due to skewed X chromosome inactivation. Estimates of the prevalence ranging from 0.9:100,000 to 4.5:100,000 have been reported. [40] [41] [42] 
Retina
Pigmentary retinopathy has been described in patients with the severe form and, to a lesser degree, in the attenuated form. [44] [45] [46] Apart from night blindness, visual impairment based on retinal degeneration is rare. 43 
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Optic Nerve
Papilloedema in the absence of increased intracranial pressure with subsequent optic atrophy is not uncommon, and may result from scleral thickening due to GAG deposition. 38, 47 Glaucoma Glaucoma is uncommon in MPS II.
Enzyme-replacement Therapy
Recombinant human iduronate-2-sulphatase (Elaprase ® , idursulfase) was recently approved as a treatment of patients with Hunter disease based on evidence demonstrating its capacity to improve walking distance and joint mobility and to reduce hepatosplenomegaly. 48 
Ocular Features

Cornea
Moderate to severe corneal clouding is common, especially in cases with more attenuated disease, 6 and frequently leads to visual impairment.
Retina
Although retinopathy has been reported in some cases, 50 ,51 it appears to be a rare feature in MPS IV. Night blindness may be reported. 49 
Optic Nerve
Optic disc swelling is commonly observed and may progress to optic nerve atrophy due to a combination of increased intraocular pressure, GAG storage in optic nerve ganglion cells and/or compression effects. 49 
Glaucoma
Increased intraocular pressure is a common finding, but should be confirmed by combining applanation tonometry with pachymetry as corneal thickness may be increased. Glaucoma may be of the angle-closure or open-angle type (GAG deposition in the trabecular meshwork). 52 
Enzyme-replacement Therapy
Recombinant human arylsulfatase B (Naglazyme ® , galsulfase) is available for the treatment of patients with Maroteaux-Lamy disease. Clinical studies have demonstrated that ERT is able to rapidly reduce urinary GAG excretion and improve endurance, 53 but potential effects on the ophthalmological manifestations have not yet been reported.
Gaucher Disease
Within the group of LSDs, Gaucher disease is the most common enzyme deficiency disorder and is inherited in an autosomal recessive manner.
The underlying cause is a deficiency of the enzyme acid β-glucocerebrosidase, which is normally involved in the degradation of complex glycosphingolipids. 54 
Clinical Course
The spectrum of clinical onset and disease progression is remarkably heterogeneous and actually represents a disease continuum. Most patients suffer from the non-neuronopathic (type 1) form. In acute, rapidly fatal neuronopathic (type 2) or chronic neuronopathic Gaucher disease (type 3), patients also display neurological manifestations. 55 Bone marrow infiltration with Gaucher cells, which causes displacement of haematopoietic elements, seems to be the first step in the aetiopathology of skeletal manifestations, which are common. 56, 57 Bone crises are more prevalent in children than in adults, but can occur for the first time in the third to seventh decade. Bone fractures are not uncommon. Other key manifestations include hepatosplenomegaly, easy bruising or bleeding (thrombocytopoenia), fatigue (anaemia), gastrointestinal complaints, pulmonary disease and growth retardation. 55, 56, 58 If the disease is diagnosed early in life, the subsequent clinical course will, in general, be more severe. 58 Unfortunately, even in such cases prolonged diagnostic delays occur that may result in even more severe disease manifestations. 59 Chronic (type 3) neuronopathic disease includes several variants. 60 Patients may exhibit prominent neurological abnormalities with relatively mild visceral involvement. A typical feature in these patients is the early development of an isolated horizontal supranuclear gaze palsy characterised by slowing of conjugate horizontal saccadic eye movements. Other patients may have subtle neurological abnormalities with severe systemic disease, or systemic manifestations in combination with cardiac valve calcifications, corneal clouding, oculomotor ataxia and mental retardation.
Ocular Features
Conjunctiva
Pingueculae, prominent yellowish lesions of the bulbar conjunctiva, may appear on both the nasal and temporal sides of the corneoscleral limbus and often remain unnoticed by the patients, although they may be more prevalent than in the general population (see Figure 6) . They have been shown to contain lipid-engorged macrophages. 61 
Cornea
Milky-white opacities, presumably caused by abnormal lysosomal glucocerebroside deposits, have been reported to occur in the corneal epithelium (posterior stromal keratocytes), anterior chamber angle, ciliary body, pupillary margin, vitreous body and choroid. 62, 63 Most of the reported cases have been in neuronopathic disease. [64] [65] [66] 
Retina
Clusters of Gaucher cells on the inner surface and within the inner layers of the retina have been reported (see Figure 7) . 66 Whether they are a sign of neuronal involvement with reduced electrophysiological responses is still under investigation. Evidence for cherry-red spots in the macula in Gaucher disease is questionable. 64 Choroidal neovascularisation has been described in combination with extensive retinal pigment epithelial alterations. 61 
Saccade Initiation Failure
Patients with chronic neuronopathic type 3 disease typically develop saccade initiation failure characterised by 'lock-up' of the eyes at the limit of gaze due to a paucity of quick phases. It can be difficult to detect clinically, but is readily revealed as missed quick phases during induced optokinetic and vestibular nystagmus. 60 
Enzyme-replacement Therapy
Therapy with recombinant human β-glucocerebrosidase (Cerezyme ® , imiglucerase) is very well tolerated, highly safe, efficacious in ameliorating symptoms and signs in most disease areas and effective in preventing further disease deterioration or development of irreversible manifestations. 55, [67] [68] [69] [70] Splenectomy can be avoided, debilitating skeletal complications can be averted in many and the average life expectancy of Gaucher patients has increased, indicating a positive effect on reducing morbidity. Reported evidence of ophthalmological responses is limited, but reversal of loss of vision has been reported. 71 
Diagnosis and Genetic Counselling
In a patient with an LSD presenting with early symptoms and signs, it is likely that the consulted physician will first suspect a common, less serious disorder. However, regular follow-up visits will bring to light an increasing number of abnormalities, and may eventually raise the index of suspicion of a more serious disorder, requiring further diagnostic work-up.
Ophthalmological manifestations are frequent in MPS I, II and VI and
Fabry disease and may even be the presenting signs or symptoms that lead to clinical diagnosis. Eye manifestations also occur in patients with Gaucher disease, particularly in the neuronopathic variant.
If a clinical suspicion of LSD exists, the clinician should first request an enzyme activity assay. The most efficient and reliable method to confirm the diagnosis is an assay using peripheral blood leukocytes and an artificial substrate.
Although knowledge of the specific genetic mutation may be of some help in predicting the severity of the disease in a specific case, a more important role for genotyping relates to screening and genetic counselling of family members of the affected individual. Genetic testing of siblings, parents still at a reproductive age and members of an extended family in case of consanguinity is essential after the diagnosis has been established. The whole procedure should be accompanied by counselling by a qualified and knowledgeable genetic counsellor or geneticist, before and after testing, using validated techniques. Parents should be informed about the likelihood that siblings, relatives and future children will inherit the disease. Currently, pre-natal diagnosis can be established through enzyme deficiency testing using chorionic villi or cultured amniocytes, or by molecular analysis.
Screening of Large Populations
To identify undiagnosed cases with an LSD, large-scale screening programmes have been undertaken. 72 Increased rigidity of the cornea and sclera may falsely lead to a diagnosis of glaucoma. 36 Therefore, diagnosis of true glaucoma requires intraocular pressure measurement in combination with corneal pachymetry.
Abnormalities of tear secretion may be demonstrated in patients with
Fabry disease. In patients with neuronopathic Gaucher disease, eye movement disturbances should be evaluated on a regular basis.
It is advised to take one or more facial, slit-lamp and fundus picture to document ocular and dysmorphic characteristics over time. Ocular status should be documented once the diagnosis of LSD is ascertained and should be monitored annually, particularly if ophthalmological pathology has been found.
Opthalmological Treatments
In addition to ERT to treat systemic disease manifestations, the ophthalmologist can provide specific ophthalmic care. Visual complaints should be treated to prevent blindness. Corneal grafts or phacoemulsification should be considered if marked opacification causes visual complaints, although risks of anaesthesia and prognosis are to be evaluated carefully. Re-accumulation of substrate may occur over time.
Prescription of spectacles may be indicated. Lubricant eye drops can be prescribed for Fabry patients if tear production is deficient. 
Conclusion
Editor's Recommendations
